190 related articles for article (PubMed ID: 18626746)
1. A structural insight into CK2 inhibition.
Mazzorana M; Pinna LA; Battistutta R
Mol Cell Biochem; 2008 Sep; 316(1-2):57-62. PubMed ID: 18626746
[TBL] [Abstract][Full Text] [Related]
2. The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules.
Battistutta R; Mazzorana M; Cendron L; Bortolato A; Sarno S; Kazimierczuk Z; Zanotti G; Moro S; Pinna LA
Chembiochem; 2007 Oct; 8(15):1804-9. PubMed ID: 17768728
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
4. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
[TBL] [Abstract][Full Text] [Related]
6. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
7. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
8. Features and potentials of ATP-site directed CK2 inhibitors.
Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
[TBL] [Abstract][Full Text] [Related]
9. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.
Meggio F; Donella Deana A; Ruzzene M; Brunati AM; Cesaro L; Guerra B; Meyer T; Mett H; Fabbro D; Furet P
Eur J Biochem; 1995 Nov; 234(1):317-22. PubMed ID: 8529658
[TBL] [Abstract][Full Text] [Related]
10. Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity.
Lindenblatt D; Applegate V; Nickelsen A; Klußmann M; Neundorf I; Götz C; Jose J; Niefind K
J Med Chem; 2022 Jan; 65(2):1302-1312. PubMed ID: 34323071
[TBL] [Abstract][Full Text] [Related]
11. The dark side of protein kinase CK2 inhibition.
Cozza G; Meggio F; Moro S
Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.
Patel S; Vyas VK; Sharma M; Ghate M
Future Med Chem; 2023 Jun; 15(11):987-1014. PubMed ID: 37307219
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
15. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
Deepa P; Thirumeignanam D; Kolandaivel P
J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
[TBL] [Abstract][Full Text] [Related]
16. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
17. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
18. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
19. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]